DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

DGX·Quest Diagnostics Incorporated

$.
-. (-.%)
High
$196.00
Open
$194.26
Market Cap
21.61B
52W High
$213.50
Low
$192.35
P. Close
$195.21
P/E
21.10
52W Low
$164.65
Fwd P/E
16.73
Mean Target
$223.44
Technical Score (1D)
55
BUY
News Sentiment
51
MIXED
Quest Diagnostics' year-to-date stock performance is currently under review, with an analysis comparing its trajectory against other medical sector stocks. This assessment aims to gauge DGX's relative market standing and identify potential drivers of investor sentiment. The comparison provides context for understanding DGX's current positioning within the broader healthcare landscape. Investors will be watching to see if this relative performance shifts in the near term, potentially indicating changes in market perception or underlying business momentum.
Earnings Summary
Quest Diagnostics is a prominent provider of diagnostic testing and related services, operating within the healthcare sector's diagnostics and research industry. The company offers a wide array of clinical testing, including routine, specialized, and anatomic pathology services, serving physicians, hospitals, health plans, and pharmaceutical companies through an extensive network of laboratories and patient service centers. In its most recent reported quarters, Quest Diagnostics demonstrated a trend of exceeding analyst expectations for earnings per share. For Q4 2025, the company reported EPS of $2.42 against an estimate of $2.45, and revenue of $2.806 billion against an estimate of $2.781 billion. This followed a Q3 2025 performance where actual EPS was $2.60, surpassing the estimate of $2.50, with revenue at $2.816 billion. Looking at the prior two quarters, Q2 2025 saw actual EPS of $2.62 compared to an estimate of $2.57, and Q1 2025 had actual EPS of $2.21 versus an estimate of $2.15. This pattern indicates a consistent ability to meet or slightly exceed revenue targets when provided, and a strong track record of beating EPS estimates in recent periods. Historically, Quest Diagnostics has shown a trajectory of year-over-year revenue growth, often accompanied by positive earnings surprises, though specific historical growth rates and beat/miss patterns over extended periods are not fully detailed in the provided data. Recent news highlights an expansion of Labcorp's partnership with Epic, which could increase the accessibility of Quest Diagnostics' testing services through the Aura platform, potentially boosting testing volumes. Additionally, institutional investors have shown increased interest, with significant stake acquisitions by Generali Asset Management and Swedbank, suggesting growing confidence in the company's prospects. A strong first quarter was also reported, with revenue up 9.2% and EPS growing 13%, underscoring positive operational performance. For the upcoming quarters, investors will be watching for continued revenue growth and the company's ability to maintain its EPS beat streak, particularly in light of the expanding accessibility of its services and positive institutional investor sentiment.

EPS

EstBeatMiss
$2.05$2.27$2.49$2.71$2.92Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.82 - -
Q1'26$2.37$2.50+5.6%
Q4'25$2.45$2.42-1.4%
Q3'25$2.50$2.60+3.9%
Q2'25$2.57$2.62+1.9%
Q1'25$2.15$2.21+2.8%

Revenue

EstBeatMiss
$2.6B$2.7B$2.8B$2.9B$3.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.0B - -
Q1'26$2.8B$2.9B+2.4%
Q4'25$2.8B$2.8B+0.9%
Q3'25 - $2.8B -
Q2'25 - $2.8B -
Q1'25 - $2.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DGX Stock Snapshot

DGX is currently trading at $194.12, giving Quest Diagnostics Incorporated a market cap of 21.61B and a P/E ratio of 21.1. Today's range spans $192.35–$196.00, with shares opening at $194.26 and moving down $1.09 (0.6%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 51/100.

Over the past year DGX has traded between $164.65 and $213.50 - the current price is +17.9% off the 52-week low and -9.1% from the high. 26 analysts cover the stock with a Hold consensus and a mean 12-month target of $223.44 (range $184.00–$245.00), implying upside of +15.1%.

For fundamental investors, DGX's neutral technical phase (55/100, HOLD) is an opportunity to assess valuation without the noise of trending price action. At 21.61B in Healthcare market cap The current P/E ratio stands at 21.1., neutral sentiment (51/100) and a price of $194.12 (in the middle of its 52-week range) describe a stock where the primary value driver is fundamental rather than momentum. Annual range: $164.65–$213.50.

In neutral phases, large-cap Healthcare names like DGX are often where sector rotation debates play out quietly — at 21.61B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 55/100 (HOLD) and neutral sentiment (51/100) at $194.12 (in the middle of its 52-week range) describe a stock that is being considered rather than avoided.